ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO894

Specificity of Nefecon in Targeting Pathogenic IgA in IgA Nephropathy While Preserving Systemic Humoral Immunity

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

  • Thomas, Roisin Clare, University of Leicester College of Life Sciences, Leicester, United Kingdom
  • Nawaz, Nadia, University of Leicester College of Life Sciences, Leicester, United Kingdom
  • Barratt, Jonathan, University of Leicester College of Life Sciences, Leicester, United Kingdom
Background

Nefecon, an FDA- and EMA-approved targeted-release formulation of budesonide, is recognized for its efficacy in treating immunoglobulin (Ig) A nephropathy (IgAN) by specifically targeting the gut-associated lymphoid tissue (GALT). In the Phase 2b NEFIGAN trial, Nefecon 16 mg/day significantly reduced levels of pathogenic galactose-deficient IgA1 (Gd-IgA1) and IgA-containing immune complexes (IgA-IC) vs placebo, but not IgA1, total IgA, or total IgG. Subsequently, an interim analysis of the larger Phase 3 NefIgArd trial confirmed that Gd-IgA1 (p<0.0001) and IgA-IC (p=0.0169) were significantly reduced by 9 months of Nefecon 16 mg/day treatment vs placebo. The trial also showed significant proteinuria reduction and kidney function benefit over 2 years with Nefecon vs placebo. Here, we assess the effect of Nefecon on total serum Ig levels in NefIgArd.

Methods

In NefIgArd, patients with IgAN received Nefecon 16 mg/day or placebo for 9 months on top of supportive care, followed by a 15-month observational period off study drug. Enzyme-linked immunosorbent assays (ELISAs) were used to measure serum levels of IgA1, total IgA, and anti-tetanus toxoid antibodies (Nefecon group, n=110; placebo group, n=113), as well as serum levels of total IgG (Nefecon, n=32; placebo, n=38 [at 9 months]). An in-house ELISA was used to measure serum anti-tetanus toxoid Igs; commercial ELISAs were otherwise used. Serum Ig levels were compared between groups at baseline, 3, 6, 9, 12, and 18 months, using unpaired t-tests (significance level p<0.05).

Results

There was no significant change from baseline in anti-tetanus toxoid Igs, total IgA, or total IgG levels following Nefecon 16 mg/day treatment for 9 months. There was a slight reduction from baseline in IgA1 at 3 months with Nefecon (p=0.02), with no reductions at any other timepoint.

Conclusion

The ability of Nefecon to specifically modulate pathogenic Gd-IgA1 production in the GALT, while leaving systemic IgA responses and total IgA and IgG levels unchanged, supports its use as a generally well tolerated, targeted, locally-acting treatment option for IgAN. Unlike other B cell−directed therapies currently in development for IgAN, Nefecon does not impair systemic humoral immunity and, therefore, offers a therapeutic advantage by selectively reducing pathogenic Gd-IgA1 while preserving overall serum Ig levels.

Funding

  • Commercial Support – Calliditas Therapeutics AB